Ottimo Pharma

Ottimo Pharma is a private biotech company developing bifunctional medicines for cancer treatment. Their lead asset, Jankistomig, is a first-in-class PD1/VEGFR2 bifunctional antibody targeting immune checkpoint inhibition and angiogenesis. This innovative approach aims to improve outcomes across multiple solid tumor indications.


Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $140M

Date: 19-Dec-2024

Investors: OrbiMed, Avoro Capital, Samsara BioCapital, RTW Investments, Decheng Capital, Janus Henderson Investors, J.P. Morgan Life Sciences Private Capital, Invus, Medicxi

Markets: Biotechnology, Oncology, Health Care, Pharmaceutical

HQ: Sandwich, Kent, United Kingdom

Founded: 2017

Website: https://ottimopharma.com/

LinkedIn: https://www.linkedin.com/company/ottimo-pharma

Twitter:

Instagram:

Facebook:

Crunchbase: https://www.crunchbase.com/organization/ottimo-pharma

Pitchbook: https://pitchbook.com/profiles/company/706251-97


Leave a Comment